In the past few years, the mechanisms leading to an acquired resistance to anti-EGFR monoclonal antibodies became an important topic in metastatic colorectal cancer research. In this commentary, we briefly summarize the latest update to this field by Arena and colleagues, and discuss promising new drugs and treatment strategies that might lead to overcoming secondary resistance.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
Journal of Hematology & Oncology Open Access 19 January 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sorich, M. J. et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann. Oncol. 26, 13–21 (2015).
Arena, S. et al. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin. Cancer Res. 21, 2157–2166 (2015).
Dienstmann, R., Salazar, R. & Tabernero, J. Overcoming resistance to anti-EGFR therapy in colorectal cancer. Am. Soc. Clin. Oncol. Educ. Book e149–e156 (2015).
Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532–536 (2012).
Kearns, J. D. et al. Enhanced targeting of the EGFR network with MM-151, an oligoclonal anti-EGFR antibody therapeutic. Mol. Cancer Ther. 14, 1625–1636 (2015).
Sanchez-Martin, F. J. et al. The first-in-class anti-EGFR antibody mixture Sym004 overcomes cetuximab-resistance mediated by EGFR extracellular domain mutations in colorectal cancer. Clin. Cancer Res. http://dx.doi.org/10.1158/1078-0432.CCR-15-2400 (2016).
Siena, S. et al. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): the HERACLES trial [abstract]. J. Clin. Oncol. 33 (Suppl.), 3508 (2015).
Lee, M. S. & Kopetz, S. Current and future approaches to target the epidermal growth factor receptor and its downstream signaling in metastatic colorectal cancer. Clin. Colorectal Cancer 14, 203–218 (2015).
Santini, D. et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann. Oncol. 23, 2313–2318 (2012).
Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21, 795–801 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H.-J.L. has received honoraria for speaking and for clinical trial support from Merck Serono and Roche. M.S. declares no competing interests.
Related links
FURTHER INFORMATION
PowerPoint slides
Rights and permissions
About this article
Cite this article
Schirripa, M., Lenz, HJ. Overcoming resistance to anti-EGFR therapy — where do we stand?. Nat Rev Gastroenterol Hepatol 13, 258–259 (2016). https://doi.org/10.1038/nrgastro.2016.52
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2016.52
This article is cited by
-
Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial
Advances in Therapy (2020)
-
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
Journal of Hematology & Oncology (2017)
-
Innovative Therapeutic Strategies Targeting Colorectal Cancer Stem Cells
Current Colorectal Cancer Reports (2017)
